Search
Influenza B virus B/Brisbane/46/2015 hemagglutinin antigen (propiolactone inactivated)
go.drugbank.com/drugs/DB14441ApprovedVaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen … that it was previously exposed to.
Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (formaldehyde inactivated)
go.drugbank.com/drugs/DB14455ApprovedWithdrawnVaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen … that it was previously exposed to.
Influenza B virus B/Brisbane/9/2014 antigen (formaldehyde inactivated)
go.drugbank.com/drugs/DB14456ApprovedWithdrawnVaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen … that it was previously exposed to.
Influenza A virus A/Michigan/45/2015 X-275 (H1N1) antigen (formaldehyde inactivated)
go.drugbank.com/drugs/DB14458ApprovedVaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen … that it was previously exposed to.
Influenza A virus A/Singapore/GP1908/2015 IVR-180 (H1N1) antigen (MDCK cell derived, propiolactone inactivated)
go.drugbank.com/drugs/DB14462ApprovedWithdrawnVaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen … that it was previously exposed to.
Influenza A virus A/Singapore/GP2050/2015 (H3N2) antigen (MDCK cell derived, propiolactone inactivated)
go.drugbank.com/drugs/DB14463ApprovedWithdrawnVaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen … that it was previously exposed to.
Influenza B virus B/Hong Kong/259/2010 antigen (MDCK cell derived, propiolactone inactivated)
go.drugbank.com/drugs/DB14464ApprovedWithdrawnVaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen … that it was previously exposed to.
Influenza B virus B/Phuket/3073/2013 BVR-1B antigen (propiolactone inactivated)
go.drugbank.com/drugs/DB14470ApprovedWithdrawnVaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen … that it was previously exposed to.
Influenza B virus B/Maryland/15/2016 BX-69A antigen (formaldehyde inactivated)
go.drugbank.com/drugs/DB14559ApprovedInvestigationalVaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen … that it was previously exposed to.
Influenza B virus B/Maryland/15/2016 BX-69A antigen (UV, formaldehyde inactivated)
go.drugbank.com/drugs/DB14561ApprovedWithdrawnVaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen … that it was previously exposed to.
Synonyms: Influenza B virus B/Maryland/15/2016 BX-69A antigen (UV, formaldehyde inactivated)